The province's major scientific and technological innovation engineering project undertaken by Disha Pharmaceutical Group Co., Ltd. located in Weihai Economic and Technological Development Zone - "Construction and Industrialization of Key Technology Systems in Precision Drug Preparation and Its Industrialization" will enter the acceptance stage at the end of the year. After three years of scientific research, the project's achievements have continued to emerge, creating considerable economic benefits and social value. The related achievements have been awarded the first prize of Shandong Province's Science and Technology Progress in 2019 and 2021.
Breaking the foreign monopoly and obtaining 11 authorized invention patents
In the Disha Pharmaceutical Group research exhibition hall, there are a wide range of drugs for treating hypertension , diabetes and other diseases. Many of these are the results of the "High-end Biology, Synthesis and Formulation Technology" project.
"Our team has innovated the process enhancement technology of the synthesis and separation of specialty raw materials, realized the direct crystallization preparation of specialty raw materials, avoided the crushing process, and the product addition is greatly improved. While reducing production costs, it effectively guaranteed the stability of the product. This variety has also successfully passed the generic drug consistency evaluation ." Wang Guan, the project leader and director of the Technical Research Institute of Disha Pharmaceutical Group, said that through the implementation of this project, the quality level of the drug has been improved, the impurity rate can be reduced to less than 5% of ten thousand, and the energy consumption can be reduced by more than 30%.
This project has completed the consistency evaluation of seven drugs, including nifedipine sustained release tablets, metformin hydrochloride tablets, cefocla granules, and cefocla chewable tablets and original products. Among them, loxoprofen sodium tablets and other varieties are the first in the country to pass the consistency evaluation.
"This series of achievements has opened a green door for innovative development for Disha Pharmaceutical, which is of great significance." Wang Guan said that since he was undertaken in 2019, he has now entered the acceptance stage. The project-related achievements have won 11 authorized invention patents, published 2 papers, and won 2 first prizes for Shandong Province's scientific and technological progress in 2019 and 2021.
Reduce the cost of medication and improve the safety of patients' medication
"The technological innovation of the project broke the monopoly of foreign patents. After the relevant drugs were launched, it accelerated the replacement of similar foreign products by domestic drugs, greatly reduced the cost of medication for patients, and also greatly reduced the economic burden of national medical insurance and had significant social benefits." Wang Guan said that during the implementation period of the project, it achieved sales revenue of 550 million yuan and export revenue of more than 30 million yuan.
At the same time, during the implementation of the project, Nedisha Pharmaceutical also introduced a large number of talents, with 16 doctoral and master's degree alone, and formed a high-end chemical drug preparation technology platform and talent team to lead the upgrading of pharmaceutical technology in the province and enhance the competitiveness of my country's pharmaceutical industry in the international market.
As the "High-end Biology, Synthesis and Formulation Technology" project is about to be accepted, the "Formulation Workshop Technical Renovation Project" of Disha Pharmaceutical's municipal key project is also being promoted rapidly. The current transformation progress exceeds 70%, and it is expected to be completed in September next year. After the project is completed, 3.5 million fordostant tablets and 30 million metformin hydrochloride tablets can be produced annually, which will increase the production efficiency by 10% compared with the previous year.
"Disha Pharmaceutical will continue to increase its investment, build an independent innovation system that optimizes the combination of industry, education and research, continuously break through the technical barriers of pharmaceutical manufacturing, and produce more good medicines." Wang Guan said. (Hi Weihai Client Reporter Shen Daoyuan Correspondent Song Yi)
